文献速递前列腺癌

基于国际泌尿病理学会前列腺癌分级分组系统对PI-RADS™第2版的前瞻性评估

Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
PubMed 文献 · J Urol · 2017-03-31

2015年5月至2016年5月,339例未治疗患者前瞻性接受多参数磁共振(PI-RADS第2版)评估后行系统穿刺与磁共振-经直肠超声融合引导穿刺。PI-RADS第2版1至5类的任何前列腺癌检出率分别为25%、20.2%、24.8%、39.1%和86.9%,临床显著前列腺癌检出率分别为0%、9.6%、12%、22.1%和72.4%。

要点

  • PI-RADS第2版类别越高,前列腺癌检出率越高。
  • 临床显著前列腺癌定义为ISUP评分≥2分(即Gleason 3+4及以上)。
  • 外周带T2加权磁共振PI-RADS第2版4类的检出率显著高于外周带总体PI-RADS第2版4类。

核心结论

  • 前列腺癌检出率随PI-RADS第2版类别升高而增加。

研究设计与样本

  • 前瞻性评估339例未治疗患者,于2015年5月至2016年5月接受多参数磁共振(PI-RADS第2版)评估后行系统穿刺和磁共振-经直肠超声融合引导穿刺,病理标本应用ISUP评分。

主要发现

  • PI-RADS第2版1、2、3、4、5类的任何前列腺癌检出率分别为25%、20.2%、24.8%、39.1%、86.9%。
  • PI-RADS第2版1、2、3、4、5类的临床显著前列腺癌检出率分别为0%、9.6%、12%、22.1%、72.4%。
  • 外周带T2加权磁共振PI-RADS第2版4类的任何前列腺癌检出率为48.1%,高于外周带总体PI-RADS第2版4类的36.6%(p=0.001)。
  • 外周带T2加权磁共振PI-RADS第2版4类的临床显著前列腺癌检出率为32.6%,高于外周带总体PI-RADS第2版4类的22.9%(p=0.002)。

关键数值与推荐

  • 临床显著前列腺癌定义为ISUP评分≥2分(即Gleason 3+4及以上)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The PI-RADS™ (Prostate Imaging Reporting and Data System), version 2 scoring system, introduced in 2015, is based on expert consensus. In the same time frame ISUP (International Society of Urological Pathology) introduced a new pathological scoring system for prostate cancer. Our goal was to prospectively evaluate the cancer detection rates for each PI-RADS, version 2 category and compare them to ISUP group scores in patients undergoing systematic biopsy and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy. MATERIALS AND METHODS: A total of 339 treatment naïve patients prospectively underwent multiparametric magnetic resonance imaging evaluated with PI-RADS, version 2 with subsequent systematic and fusion guided biopsy from May 2015 to May 2016. ISUP scores were applied to pathological specimens. An ISUP score of 2 or greater (ie Gleason 3 + 4 or greater) was defined as clinically significant prostate cancer. Cancer detection rates were determined for each PI-RADS, version 2 category as well as for the T2 weighted PI-RADS, version 2 categories in the peripheral zone. RESULTS: The cancer detection rate for PI-RADS, version 2 categories 1, 2, 3, 4 and 5 was 25%, 20.2%, 24.8%, 39.1% and 86.9% for all prostate cancer, and 0%, 9.6%, 12%, 22.1% and 72.4% for clinically significant prostate cancer, respectively. On T2-weighted magnetic resonance imaging the cancer detection rate in the peripheral zone was significantly higher for PI-RADS, version 2 category 4 than for overall PI-RADS, version 2 category 4 in the peripheral zone (all prostate cancer 36.6% vs 48.1%, p = 0.001, and clinically significant prostate cancer 22.9% vs 32.6%, p = 0.002). CONCLUSIONS: The cancer detection rate increases with higher PI-RADS, version 2 categories.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mehralivand S, Bednarova S, Shih JH, et al. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. J Urol. 2017. PMID: 28373133. doi:10.1016/j.juro.2017.03.131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。